Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8367483 | 0.85 | RAB9A (0.52) | RAB9AKMT2ALMNAPOLBTSHR | |
| SCHEMBL4629666 | 0.80 | ALDH1A1 (0.57) | RAB9ALMNAKDM4EALDH1A1CA12 | |
| SCHEMBL4629544 | 0.79 | ALDH1A1 (0.56) | RAB9ALMNAKDM4EALDH1A1CA12 | |
| SCHEMBL2224971 | 0.79 | MCHR1 (0.36) | TRPV1TSHRSLC40A1 | |
| SCHEMBL27578438 | 0.78 | TRPV1 (0.44) | TRPV1KMT2ACYP1A2 | |
| SCHEMBL4629901 | 0.75 | ALDH1A1 (0.58) | RAB9ALMNAKDM4EALDH1A1CA12 | |
| SCHEMBL2377244 | 0.75 | ALDH1A1 (0.54) | RAB9AKMT2ALMNAPOLBKDM4E | |
| SCHEMBL859430 | 0.74 | TRPV1 (0.56) | TRPV1KMT2ACYP1A2 | |
| SCHEMBL2295373 | 0.74 | ALDH1A1 (0.48) | RAB9AKMT2ALMNAKDM4EALDH1A1 | |
| SCHEMBL6114625 | 0.73 | TRPV1 (0.58) | TRPV1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR3B, HTR1A | TRPV1 353/4885RAB9A 1928/4885KMT2A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.